In the commercial market, GLP1 prescription volume grew from 680,000 in January 2020 to 4.7 million in May 2025
BMC Biol
For instance, past studies show that GLP-1s may also aid in treating cardiovascular disease, chronic kidney disease, non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and rheumatic diseases, such as rheumatoid arthritis and osteoarthritis
Thats because Medicare, rather than the Part D insurer, is subsidizing the prescription
GLP-1 Use Cases and Barriers to Entry The primary use case for GLP-1 medications is shifting
It therefore cannot be legally prescribed or dispensed through NHS or private pharmacy channels in the UK outside of a formal clinical trial setting